wire - news in brief


Category


Years
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008

Last News


Results 1 - 50 of 342.
1 2 3 4 5 7 Next »

Physics/Materials Science - Environment/Sustainable Development
20.09.2017
World record solar cells for
World record solar cells for "move"
Swiss start-up Flisom is ready for the global market: The company, a spin-off from ETH Zürich and Empa, has developed a unique roll-to-roll process for the cost-effective production of flexible and highly efficient thin-film solar modules.
Physics/Materials Science - Life Sciences
20.09.2017
X-ray and neutron imaging for palaeontologists and archaeologists
The interior of fossils and artefacts that are hundreds, thousands and yes, sometimes millions of years old can be examined at two PSI research facilities. A conversation with Federica Marone and Eberhard Lehmann, who are opening a new view into the past with their methods. Ms. Marone, Mr. Lehmann  -  palaeontologists and archaeologists regularly come to you to look inside fossils and ancient objects with your non-destructive analysis methods.
Computer Science/Telecom
20.09.2017
Drones can almost see in the dark
A conventional camera and an event camera (on the right) picture the same building. The latter reports changes in brightness for each pixel.
Medicine/Pharmacology - Life Sciences
20.09.2017
Novartis drug Rydapt (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
Novartis drug Rydapt (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM) Significant overall surviv
Medicine/Pharmacology
18.09.2017
Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan
Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan Data from pivotal phase III study will be submitted to health authorities and presented at an upcoming medical meeting Roche announced today that the phase III MURANO study, which evaluated Venclexta /Venclyxto (venetocla
Medicine/Pharmacology - Life Sciences
16.09.2017
Novartis’ Xolair confirms re-treatment efficacy in chronic spontaneous urticaria patients after treatment interruption
OPTIMA Phase IIIb data re-confirm that almost two thirds of patients treated with Xolair 300 mg for 6 months are well-controlled   Should a treatment pause be necessary, data showed almost 90% of chronic spontaneous urticaria (CSU) patients - previously well controlled - regained effective symptom control within 12 weeks of re-treatment on Xolair   Previous studies have shown that inadequately controlled CSU has a major impact on sleep, social l
Medicine/Pharmacology - Environment/Sustainable Development
15.09.2017
The University of Bern on the move
Media releases, information for representatives of the media Media Relations (E) Research at the University of Bern is being intensified: Innovative joint projects from different subject areas are being supported with the new Interfaculty Research Cooperations IRC.
Medicine/Pharmacology
15.09.2017
Life Expectancy Increases in Switzerland
Life Expectancy Increases in Switzerland
Countries have saved more lives over the past decade according to the annual Global Burden of Diseases (GBD) study published yesterday. In Switzerland, life expectancy has increased to 85 years for women and to 81 years for men. The Swiss Tropical and Public Health Institute contributed to the GDB, the world's largest scientific collaboration on population health.
Physics/Materials Science
15.09.2017
Second lease of life for used batteries
Second lease of life for used batteries
What can we do with aging scooter batteries' Instead of scrapping them and recycling their components, the batteries could be left intact and re-used in a solar power storage cabinet.
Medicine/Pharmacology - Psychology
15.09.2017
New Study on the Placebo Effect and Antidepressants in Children and Adolescents
New Study on the Placebo Effect and Antidepressants in Children and Adolescents
Although the clinical efficacy of antidepressants in children and adolescents is proven, it is frequently accompanied by side effects. In addition, the influence of the placebo effect on the efficacy of antidepressants is unclear. A meta-analysis of data from over 6,500 patients has now shown that, although antidepressants are more effective than placebos, the difference is minor and varies according to the type of mental disorder.
Medicine/Pharmacology
14.09.2017
Parasitic Worms in Siberia
Parasitic Worms in Siberia
Millions of people worldwide are infected with parasitic worms, most of them in tropical low-income settings.
Medicine/Pharmacology - Life Sciences
14.09.2017
Increase of antibiotic resistance - Antibiotic Awareness Week highlights the risks
Bern, 14.09.2017 - The global fight against antibiotic resistance is ramping up. The World Health Organization has launched an Antibiotic Awareness Week, which will be running for the first time in Switzerland from 13 to 19 November 2017.
Physics/Materials Science
14.09.2017
The hard worker from Val Mesolcina
For Aldo Antognini, physics and conviviality are in the blood PSI researcher Aldo Antognini has received more than 2.2 million Swiss francs from the EU for his latest experiment.
Medicine/Pharmacology - Life Sciences
14.09.2017
Sandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study
51-week clinical study confirms that Sandoz proposed biosimilar adalimumab matches reference medicine Humira * safety and efficacy profile Sandoz proposed biosimilar adalimumab is currently under review by the European Medicines Agency for the treatment of several immunological diseases Sandoz expects that approval of biosimilar adalimumab would further improve access to treatment for people living with immunological diseases Holzkirchen, Septem
Medicine/Pharmacology - Life Sciences
13.09.2017
Vessels that help cancers spread can also boost cancer immunotherapy
Vessels that help cancers spread can also boost cancer immunotherapy
Scientists from Switzerland and the US have shown that lymphatic vessels can enable both metastasis and T-cell invasion, opening new paths for cancer immunotherapy. Many cancers, such as melanoma, are known to metastasize and spread by expanding nearby lymphatic vessels. This process, lymphangiogenesis, also helps the tumor evade the patient's own immune system, and it would be expected that inhibiting lymphangiogenesis, could enhance the efficacy of cancer immunotherapies, which are only effective in a minority of patients.
Microtechnics/Electroengineering
13.09.2017
World's largest electric vehicle
World’s largest electric vehicle
A Swiss consortium of companies is constructing the largest electric vehicle in the world - in record time.
Medicine/Pharmacology
13.09.2017
Novartis’ Cosentyx sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data
Cosentyx (secukinumab) is the first and only fully human IL-17A   inhibitor to show sustained skin clearance rates at 5 years in phase III in psoriasis   Landmark data show that PASI 90 and PASI 100
Physics/Materials Science - Microtechnics/Electroengineering
13.09.2017
Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material
Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material
For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale.
Environment/Sustainable Development
12.09.2017
Medicine/Pharmacology - Life Sciences
12.09.2017
Sandoz proposed biosimilar rituximab accepted for review by the FDA
Rituximab is indicated to treat blood cancers and immunological diseases such as rheumatoid arthritis Sandoz believes the comprehensive data package submitted to the FDA for review confirms that our
Physics/Materials Science
11.09.2017
Using Mirrors to Improve the Quality of Light Particles
Using Mirrors to Improve the Quality of Light Particles
Scientists from the University of Basel's Department of Physics and the Swiss Nanoscience Institute have succeeded in dramatically improving the quality of individual photons generated by a quantum system. The scientists have successfully put a 10-year-old theoretical prediction into practice. With their paper, published recently in Physical Review X, they have taken an important step towards future applications in quantum information technology.
Medicine/Pharmacology
11.09.2017
Roche announces phase III study results of Zelboraf for adjuvant treatment of BRAF V600 mutation-positive melanoma
Roche announces phase III study results of Zelboraf for adjuvant treatment of BRAF V600 mutation-positive melanoma Roche today announced data for the phase III BRIM8 study, which was designed to investigate the efficacy and safety of Zelboraf (vemurafenib) in the adjuvant (after surgery) treatment of people with completely resected, BRAF V600 mutation-positive melanoma.
Medicine/Pharmacology - Media
11.09.2017
Adjuvant Tafinlar + Mekinist reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma
Novartis Phase III study demonstrates adjuvant Tafinlar + Mekinist reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma The three-year relapse
Medicine/Pharmacology - Life Sciences
09.09.2017
Novartis presents new data at EURETINA 2017 confirming Lucentis efficacy and durability vs aflibercept
Interim results of the head-to-head RIVAL study confirm strong efficacy and comparable durability versus aflibercept in patients with nAMD   Five-year results from the Lucentis LUMINOUS study, the largest ever in retinal disease, demonstrate real-world efficacy and safety across five retinal diseases Novartis, the global leader in ophthalmology, today reported new data confirming Lucentis (ranibizumab) efficacy and durability in patients with nAMD at the 17 th EURETINA Congress in Barcelona, Spain (September 7-10, 2017).
Medicine/Pharmacology - Earth Sciences
08.09.2017
Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration
Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration Spectri study did not meet its primary endpoint of reducing mean change in geographic atrophy lesion area in patients treated with lampalizumab compared with sham treatment Safety profile was in line with previous lampalizumab trials and other intravitreal therapies Results from the second phase III study, Chro
Medicine/Pharmacology - Life Sciences
08.09.2017
Roche announces progress in biomarker science in cancer immunotherapy at the European Society for Medical Oncology Congress
Roche announces progress in biomarker science in cancer immunotherapy at the European Society for Medical Oncology Congress First data on new blood-based assay for measuring tumour mutational burden Two prospective studies underway to assess the potential of tumour mutational burden to predict response to certain cancer immunotherapies Roche announced today that the first data on a novel blood-based assay, co-developed with Foundation Medicine (NASDAQ: FMI), will be presented during the European Society for Medical Oncology (ESMO) Congress from 8-12 September 2017 in Madrid, Spain.
Careers/Employment - Academic Rankings
07.09.2017
Six EPFL startups are among the Swiss top 10
Six EPFL startups are among the Swiss top 10
L.E.S.S. and Flyability - two EPFL startups - are among the podium finishers in the latest TOP 100 Swiss Startups ranking, which was announced yesterday evening in Zurich.
Astronomy - Media
07.09.2017
50 years of space exploration at the University of Bern
50 years of space exploration at the University of Bern
Media releases, information for representatives of the media Media Relations (E) This year, the University of Bern celebrates 50 years of space exploration.
Physics/Materials Science - Computer Science/Telecom
07.09.2017
High-speed Quantum Memory for Photons
High-speed Quantum Memory for Photons
Physicists from the University of Basel have developed a memory that can store photons. These quantum particles travel at the speed of light and are thus suitable for high-speed data transfer.
Medicine/Pharmacology - Life Sciences
07.09.2017
Novartis presents new analysis demonstrating AMG 334 (erenumab) significantly reduced monthly migraine days in patients who failed previous preventive therapies
Novartis presents new analysis demonstrating AMG 334 (erenumab) significantly reduced monthly migraine days in patients who failed previous preventive therapies AMG 334 (erenumab) delivered consistent reductions in monthly migraine days for patients with chronic migraine and prior treatment failure, a population with significant unmet need   Dedicated cardiovascular safety study reaffirmed placebo-like tolerability of erenumab as seen consisten
Politics - Environment/Sustainable Development
06.09.2017
Mercury: first Minamata Convention conference in Geneva
Bern, 06.09.2017 - The first Conference of the Parties to the Minamata Convention will take place from 24 to 29 September in Geneva.
Medicine/Pharmacology - Life Sciences
06.09.2017
Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer
Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer ALUR study shows 85% reduction in risk of disease worsening or death versus chemotherapy in patients with advanced ALK-positive NSCLC who had progressed on chemotherapy and crizotinib Roche today announced results from the global phase III ALUR study showing that Alecensa significantly reduc
Physics/Materials Science - Astronomy
06.09.2017
Particle physicists on a quest for
Particle physicists on a quest for "new physics"
EPFL's physicists are moving forward in their efforts to solve the mysteries of the universe. A particle detector made up of 10,000 kilometers of scintillating fiber is under construction and will be added onto CERN's particle accelerator.
Medicine/Pharmacology
05.09.2017
Medicine/Pharmacology - Life Sciences
05.09.2017
Tuberculosis Research Against "Super Resistant Bacteria"
To fall ill from tuberculosis remains a great danger. A research team led by cell biologist Sébastien Gagneux at the Swiss Tropical and Public Health Institute (Swiss TPH) examines the antibiotic resistance mechanisms of Mycobacterium tuberculosis.
Medicine/Pharmacology
05.09.2017
Medicine/Pharmacology - Life Sciences
05.09.2017
Novartis landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MS
Phase III PARADIGMS study in pediatric MS met its primary endpoint, showing a significant reduction in relapses occur with fingolimod versus interferon beta-1a   There is a significant unmet need for safe and effective MS treatments for children and adolescents, for whom there are no specifically approved disease-modifying therapies   Children and adolescents living with MS face physical and cognitive disability that severely limits their ability to go about daily activities, such as going to school     PARADIGMS is a first of its kind study in pediatric MS.
Life Sciences - Environment/Sustainable Development
05.09.2017
Combating Japanese Beetles with Fungi
Zurich-Reckenholz, 05.09.2017 - In June of this year, the Japanese beetle (Popillia japonica) was detected for the first time in Switzerland, in the canton of Ticino. Considered to be a quarantine pest, it is subject to obligatory control. Agroscope researchers are testing whether this quarantine pest can be controlled with fungi that are effective against May and June beetles.
Life Sciences
05.09.2017
First Detailed Decoding of Complex Finger Millet Genome
First Detailed Decoding of Complex Finger Millet Genome
For many poor farmers in India and Africa, finger millet is a major staple food. The crop species is not only a rich source of minerals like calcium, iron, magnesium and zinc, and it contains many vitamins and essential amino acids.
Computer Science/Telecom
04.09.2017
Medicine/Pharmacology - Business/Economics
04.09.2017
Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018
Basel, September 4, 2017 - Joseph Jimenez, Chief Executive Officer (CEO) of Novartis, has informed the Board of Directors of his desire to step down as CEO in 2018, after eight years in position.
Physics/Materials Science - Life Sciences
04.09.2017
Like a Revolving Door: How Shuttling Proteins Operate Nuclear Pores
Like a Revolving Door: How Shuttling Proteins Operate Nuclear Pores
Nuclear pore complexes are tiny channels where the exchange of substances between the cell nucleus and the cytoplasm takes place. Scientists at the University of Basel report on startling new research that might overturn established models of nuclear transport regulation. Their study published in the Journal of Cell Biology reveals how shuttling proteins known as importins control the function of nuclear pores - as opposed to the view that nuclear pores control the shuttling of importins.
Environment/Sustainable Development - Earth Sciences
04.09.2017
Diverse Landscapes Are More Productive and Adapt better to Climate Change
Diverse Landscapes Are More Productive and Adapt better to Climate Change
The dramatic, worldwide loss of biodiversity is one of today's greatest environmental problems. The loss of species diversity affects important ecosystems on which humans depend. Previous research predominantly addressed short-term effects of biodiversity in small experimental plots planted with few randomly selected plant species.
Business/Economics
03.09.2017
Huge interest in the world of data
Big data, digitalisation, artificial intelligence, Internet of Things - these terms are on everybody's lips these days, but what exactly do they mean?
Environment/Sustainable Development - Event
01.09.2017
Environment/Sustainable Development - Event
01.09.2017
Medicine/Pharmacology - Business/Economics
31.08.2017
Roche to present new data from its oncology portfolio at the 2017 European Society for Medical Oncology (ESMO) Congress
Roche to present new data from its oncology portfolio at the 2017 European Society for Medical Oncology (ESMO) Congress Data from 18 approved and investigational cancer medicines to be presented at ESMO 2017 Results for Zelboraf (vemurafenib) as an adjuvant treatment for BRAF V600 mutation-positive melanoma to feature in the ESMO Presidential Symposium New data from phase III ALEX and ALUR studies provide additional evidence supporting the use o
1 2 3 4 5 7 Next »

 
 
Logo Careerjet